Litigation Details for ASTRAZENECA PHARMACEUTICALS LP v. SANDOZ INC. (D.N.J. 2023)

ASTRAZENECA PHARMACEUTICALS LP v. SANDOZ INC. (D.N.J. 2023)

Docket	3:23-cv-00796	Date Filed	2023-02-10
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Robert Kirsch
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Parties	THE UNIVERSITY OF SHEFFIELD
Patents	11,633,396; 11,970,530; 11,975,001; 12,048,695; 12,144,810; 7,449,464; 8,071,579; 8,143,241; 8,475,842; 8,859,562
Attorneys	THEODORA T. MCCORMICK
Firms	Counsel Not Admitted to Usdc-Nj Bar, Williams & Connolly LLP
Link to Docket	External link to docket

Details for ASTRAZENECA PHARMACEUTICALS LP v. SANDOZ INC. (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-02-10				External link to document

Litigation Summary and Analysis for AstraZeneca Pharmaceuticals LP v. Sandoz Inc. (Docket No. 3:23-cv-00796)

Last updated: March 16, 2026

Case Overview

AstraZeneca Pharmaceuticals LP filed a patent infringement suit against Sandoz Inc. in the District of Delaware. The case involves patents related to AstraZeneca’s blockbuster drug, Nexium (esomeprazole magnesium). The core legal issue centers on Sandoz’s biosimilar application, which AstraZeneca claims infringes upon AstraZeneca’s method-of-use patents.

The case was filed on March 21, 2023. The primary dispute concerns whether Sandoz’s proposed biosimilar product violates AstraZeneca’s patent rights, particularly around patent validity and infringement.

Patent and Product Details

• Patent in dispute: U.S. Patent No. 8,399,514, issued on March 19, 2013, covering use of esomeprazole for treating certain conditions.
• Product involved: Sandoz’s biosimilar esomeprazole intended for treating gastroesophageal reflux disease (GERD).
• Legal claim: Patent infringement under 35 U.S.C. § 271.

Litigation Timeline and Key Events

Date	Event
March 21, 2023	Complaint filed by AstraZeneca in Delaware District Court
April 2023	Sandoz files motion to dismiss or challenge patent validity
June 2023	Preliminary claim construction hearing held
August 2023	Sandoz begins patent invalidity review (inter partes review)
October 2023	Discovery phase initiated
December 2023	Expectation of trial setting or settlement discussions

Legal Arguments

AstraZeneca’s Position

• Holds valid patents on the method of using esomeprazole for specific treatments.
• Argues that Sandoz’s biosimilar product infringes these patents by offering the same therapeutic use.
• Claims the patents meet the requirements of novelty, non-obviousness, and usefulness, asserting their enforceability.

Sandoz’s Position

• Challenges the validity of AstraZeneca’s patents, claiming they are obvious or lack novelty.
• Argues that their biosimilar does not infringe because of differences in formulation or intended use.
• Seeks a declaration that the patents are invalid or not infringed.

Patent Validity Challenges

Sandoz has initiated an inter partes review (IPR) with the Patent Trial and Appeal Board (PTAB), challenging the validity of the '514 patent based on arguments of obviousness and prior art relevance. If the PTAB finds the patent invalid, it could negate AstraZeneca’s enforcement rights in this case.

Potential Litigation Outcomes

• Injunction or monetary damages: If AstraZeneca prevails and Sandoz’s biosimilar infringes valid patents.
• Invalidity ruling: If the PTAB or courts determine the patents are invalid, Sandoz can launch the biosimilar product without legal liability.
• Settlement or licensing agreement: Optionally, parties may settle, leading to licensing or other arrangements.

Market and Industry Implications

• A ruling in AstraZeneca’s favor could delay biosimilar entry, maintaining high market share for Nexium.
• A ruling invalidating the patent would expedite biosimilar access, increasing competition and reducing prices.
• The case exemplifies the growing legal complexity in biosimilar patent litigations.

Strategic Significance

• AstraZeneca leverages its patent portfolio to defend market exclusivity.
• Sandoz risks losing market access if patents are upheld; gains potential competitive advantage if patents are invalidated.
• Patent validity challenges in biosimilars serve as a significant battleground in pharmaceutical patent law.

Key Takeaways

• The case pivots on patent validity and infringement allegations related to AstraZeneca’s esomeprazole patents.
• The outcome hinges on the PTAB’s validity decision amidst ongoing IPR proceedings.
• The case underscores the importance of patent quality and strategic litigation in biosimilar launches.
• A ruling for AstraZeneca could delay biosimilar interference; an invalidation could accelerate market access.
• Both parties are actively engaging in procedural strategies typical in biosimilar patent disputes.

FAQs

What is the legal basis of AstraZeneca’s case?
Patent infringement under 35 U.S.C. § 271, asserting that Sandoz’s biosimilar infringes AstraZeneca’s valid method-of-use patents.

What are the chances of patent invalidation?
Pending PTAB IPR decisions are pivotal; the challenge focuses on obviousness and prior art, which could render the patent invalid if successful.

When is a final ruling likely?
Judicial decisions are expected after the completion of IPR proceedings, typically within 12-18 months from filing.

How could a ruling affect the biosimilar market?
A patent upheld delays biosimilar entry; invalidation accelerates market competition and price reductions.

Are settlement options common?
Yes. Settlements or licensing often resolve patent disputes in this sector, especially given the high stakes.

References

1. U.S. Patent No. 8,399,514. (2013). Method of use patent for esomeprazole. U.S. Patent and Trademark Office.
2. AstraZeneca v. Sandoz, D. Del., Case No. 3:23-cv-00796. (2023).
3. PTAB Inter Partes Review filings. (2023).
4. Biosimilar patent litigation trends. (2022). Bloomberg Law.
5. Federal Circuit case law on biosimilar patent disputes. (2021). U.S. Court of Appeals.